Esperion Stock Analysis

ESPR
 Stock
  

USD 6.18  0.15  2.37%   

Esperion Therapeutics price fall over the last few months could raise concerns from retail investors as the firm is trading at a share price of 6.18 on very low momentum in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in November. However, diversifying your holdings with Esperion Therapeutics or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.05. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Esperion Therapeutics partners.
Continue to Investing Opportunities.
  
The Esperion Therapeutics stock analysis report makes it easy to digest most publicly released information about Esperion Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Esperion Stock analysis module also helps to analyze the Esperion Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Esperion Stock Analysis Notes

About 88.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 6.24. Esperion Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 11th of June 2013. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Esperion Theraptc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 218 people. To learn more about Esperion Therapeutics call Sheldon Koenig at 734 887 3903 or check out https://www.esperion.com.

Esperion Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Esperion Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Esperion Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Esperion Therapeutics generated a negative expected return over the last 90 days
Esperion Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 78.45 M. Net Loss for the year was (269.11 M) with loss before overhead, payroll, taxes, and interest of (41.74 M).
Esperion Therapeutics currently holds about 185.84 M in cash with (263.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79.
Over 88.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022 - Investing News Network

Esperion Therapeutics Upcoming and Recent Events

Earnings reports are used by Esperion Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Esperion Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Esperion Largest EPS Surprises

Earnings surprises can significantly impact Esperion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-03-05
2014-12-31-0.55-0.490.0610 
2013-11-06
2013-09-30-0.4-0.340.0615 
2015-05-07
2015-03-31-0.48-0.56-0.0816 
View All Earnings Estimates

Esperion Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Esperion Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Esperion Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Esperion Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
23rd of August 2022
Unclassified Corporate Event
View
2nd of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
13th of June 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
1st of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
26th of May 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
View
17th of May 2022
Unclassified Corporate Event
View
3rd of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Esperion Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 455.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Esperion Therapeutics's market, we take the total number of its shares issued and multiply it by Esperion Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Esperion Profitablity

Esperion Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Esperion Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Esperion Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Esperion Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Esperion Therapeutics' profitability requires more research than a typical breakdown of Esperion Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(313.66) (338.43) 
Return on Average Assets(73.24) (79.02) 
Return on Average Equity(225.58) (231.52) 
Return on Invested Capital(0.45) (0.48) 
Return on Sales(2.84) (2.92) 

Management Efficiency

The entity has return on total asset (ROA) of (0.4475) % which means that it has lost $0.4475 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.6079) %, meaning that it created substantial loss on money invested by shareholders. Esperion Therapeutics management efficiency ratios could be used to measure how well esperion therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/09/2022, Return on Investment is likely to drop to -338.43. In addition to that, Return on Average Assets is likely to drop to -79.02. Esperion Therapeutics Total Assets are relatively stable at the moment as compared to the past year. Esperion Therapeutics reported last year Total Assets of 381.59 Million. As of 12/09/2022, Current Assets is likely to grow to about 354.9 M, while Net Current Assets as percentage of Total Assets are likely to drop 54.51.
Last ReportedProjected for 2022
Book Value per Share(6.81) (7.35) 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(2.32) (2.51) 
Price to Book Value(0.74) (0.76) 
Tangible Assets Book Value per Share 13.20  11.67 
Enterprise Value515.5 M737.7 M
Tangible Asset Value381.5 M313.5 M
Non Current Liabilities Total
505.2 M
Short Long Term Debt Total
260.2 M
Interest Expense
46.4 M
Total Operating Expenses
291 M
Beta
0.2173
Common Stock Total Equity
61 K

Technical Drivers

As of the 9th of December, Esperion Therapeutics shows the mean deviation of 3.17, and Coefficient Of Variation of (1,533). Esperion Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Esperion Therapeutics, which can be compared to its rivals. Please confirm Esperion Therapeutics standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Esperion Therapeutics is priced favorably, providing market reflects its regular price of 6.18 per share. Given that Esperion Therapeutics has jensen alpha of (0.30), we urge you to verify Esperion Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Esperion Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Esperion Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Esperion Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Esperion Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Esperion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Esperion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Esperion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Esperion Therapeutics Technical and Predictive Indicators

Esperion Therapeutics Forecast Models

Esperion Therapeutics time-series forecasting models is one of many Esperion Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Esperion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Esperion Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Esperion Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Esperion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Esperion Therapeutics. By using and applying Esperion Stock analysis, traders can create a robust methodology for identifying Esperion entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(48.01) (51.81) 
EBITDA Margin(47.61) (51.37) 
Gross Margin 81.88  95.44 
Profit Margin(56.78) (61.26) 

Current Esperion Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Esperion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Esperion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.88Hold8Odds
Esperion Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Esperion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Esperion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Esperion Therapeutics, talking to its executives and customers, or listening to Esperion conference calls.
Esperion Analyst Advice Details

Esperion Stock Analysis Indicators

Esperion Therapeutics stock analysis indicators help investors evaluate how Esperion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Esperion Therapeutics shares will generate the highest return on investment. By understating and applying Esperion Therapeutics stock analysis, traders can identify Esperion Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow304962000.00
Logo U R LimglogosUSESPR.png
Common Stock Shares Outstanding26455209.00
Total Stockholder Equity-196944000.00
Total Cashflows From Investing Activities-50484000.00
Property Plant And Equipment Net2562000.00
Retained Earnings-1106377000.00
Cash And Short Term Investments259333000.00
Retained Earnings Total Equity-1106377000.00
Cash208892000.00
CodeESPR
Accounts Payable17559000.00
Net Debt51304000.00
50 Day M A7.5292
Total Current Liabilities73352000.00
Currency CodeUSD
Other Operating Expenses305177000.00
Non Current Assets Total52618000.00
Common Stock Total Equity61000.00
Non Currrent Assets Other-385000.00
Continue to Investing Opportunities. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Esperion Therapeutics price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
455.4 M
Quarterly Revenue Growth YOY
0.317
Return On Assets
(0.45) 
Return On Equity
(2.61) 
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Esperion Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.